Mabion (STU:272) E10: €-0.81 (As of Mar. 2026)


STU:272 Mabion SA STU:272
25 GF Score
Price €1.62
GF Value €0.47
! 4 Warning Signs
View Full Analysis

What is Mabion E10?

Mabion STU:272 -0.61% 25 E10 is €-0.81 as of Mar. 2026. GuruFocus rates STU:272 with a GF Score™ of 25/100 and a GF Value™ of €0.47. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Mabion's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.139. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.81 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Mabion was 0.90% per year. The lowest was -3.70% per year. And the median was -1.40% per year.

As of today (2026-07-07), Mabion's current stock price is €1.618. Mabion's E10 for the quarter that ended in Mar. 2026 was €-0.81. Mabion's Shiller PE Ratio of today is .


Mabion  (STU:272) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Mabion E10 Related Terms


Mabion E10 Historical Data

* Premium members only.

The historical data trend for Mabion's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabion E10 Chart

Mabion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.70 -0.77 -0.80 -0.84 -0.82

Mabion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -0.88 -0.91 -0.82 -0.81

STU:272 vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Mabion's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabion Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabion's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mabion's Shiller PE Ratio falls into.


STU:272
25GF Score
Mabion SA STU:272
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mabion E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mabion's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.139/163.0700*163.0700
=-0.139

Current CPI (Mar. 2026) = 163.0700.

Mabion Quarterly Data

per share eps CPI Adj_EPS
201606 -0.280 99.552 -0.459
201609 -0.284 99.064 -0.467
201612 -0.344 100.366 -0.559
201703 -0.254 101.018 -0.410
201706 -0.245 101.180 -0.395
201709 -0.178 101.343 -0.286
201712 -0.379 102.564 -0.603
201803 -0.282 102.564 -0.448
201806 -0.474 103.378 -0.748
201809 -0.220 103.378 -0.347
201812 -0.277 103.785 -0.435
201903 -0.252 104.274 -0.394
201906 -0.282 105.983 -0.434
201909 -0.282 105.983 -0.434
201912 -0.257 107.123 -0.391
202003 -0.335 109.076 -0.501
202006 -0.185 109.402 -0.276
202009 -0.153 109.320 -0.228
202012 -0.266 109.565 -0.396
202103 -0.287 112.658 -0.415
202106 -0.035 113.960 -0.050
202109 -0.224 115.588 -0.316
202112 0.532 119.088 0.728
202203 0.106 125.031 0.138
202206 0.074 131.705 0.092
202209 -0.072 135.531 -0.087
202212 0.224 139.113 0.263
202303 0.236 145.950 0.264
202306 0.217 147.009 0.241
202309 0.155 146.113 0.173
202312 -0.018 147.741 -0.020
202403 0.252 149.044 0.276
202406 0.148 150.997 0.160
202409 -0.234 153.439 -0.249
202412 -0.254 154.660 -0.268
202503 -0.217 157.021 -0.225
202506 -0.220 157.509 -0.228
202509 -0.155 158.000 -0.160
202512 -0.303 158.320 -0.312
202603 -0.139 163.070 -0.139

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.81 mean?
Mabion (STU:272) has a E10 of €-0.81 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Mabion and its competitors.
Is Mabion's E10 too high?
Mabion's current E10 is €-0.81. Overall, Mabion has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Mabion's E10 compare to VRTX and REGN?
Mabion's E10 of €-0.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Mabion and its competitors. Mabion's current E10 is €-0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Mabion (STU:272) has a current E10 of €-0.81. The stock's GF Value™ is €0.47, compared to a current price of €1.62 — trading 244.3% above its estimated fair value. The current E10 is €-0.81. Mabion's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Mabion (STU:272), the current E10 is €-0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabion (STU:272) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of €1.62 is trading 244.3% above its estimated GF Value™ of €0.47.

Key valuation signals for STU:272:

  • E10: €-0.81
  • GF Value™: €0.47 vs. price of €1.62 (244.3% above fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the STU:272 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mabion Business Description

Other Exchanges MAB:Poland272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
25GF Score

Get the complete analysis for STU:272

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price
€0.47
GF Value